pancreatic cancer

[Biochimica et Biophysica Acta-Reviews On Cancer] Scientists describe the involvement of p53 signaling reactivation in pancreatic cancer (PC) treatment as well as its underlying molecular mechanisms, thereby providing useful insights for targeting p53-related signal pathways in PC therapy.

[Nature Communications] Scientists demonstrated a previously undescribed tumor cell-intrinsic role for glucocorticoid receptor (GR) in activating PD-L1 expression and repressing the major histocompatibility complex class I expression in pancreatic ductal adenocarcinoma cells through transcriptional regulation.

[Cell] Researchers identified a gene signature defining CAR and TCR dysregulation and transcription factors, including SOX4 and ID3 as key regulators of CAR T cell exhaustion.

[Oncotelic Therapeutics, Inc.] Oncotelic Therapeutics, Inc. announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase II Trial for OT-101, the company’s TGF-β inhibitor, in combination with Anti-PD-1 as a treatment for patients with malignant pleural mesothelioma.

[Clinical and Translational Oncology] Researchers investigated the effects of exosomes extracted from human umbilical cord mesenchymal stem cells carrying hsa-miRNA-128-3p on pancreatic cancer cells.

[Cell Death & Disease] Researchers probed the function and potential mechanism of KCNK15-AS1 in pancreatic cancer (PC) cell growth. RT-qPCR and western blot were employed to measure gene expression in PC cells.